A detailed history of Redmile Group, LLC transactions in Achilles Therapeutics PLC stock. As of the latest transaction made, Redmile Group, LLC holds 1,608,089 shares of ACHL stock, worth $1.72 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
1,608,089
Previous 1,608,089 -0.0%
Holding current value
$1.72 Million
Previous $1.32 Million 24.43%
% of portfolio
0.11%
Previous 0.09%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$2.8 - $5.23 $1.34 Million - $2.51 Million
-480,000 Reduced 22.99%
1,608,089 $4.73 Million
Q1 2021

May 17, 2021

BUY
$16.55 - $16.55 $34.6 Million - $34.6 Million
2,088,089 New
2,088,089 $34.6 Million

Others Institutions Holding ACHL

About Achilles Therapeutics plc


  • Ticker ACHL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,774,000
  • Market Cap $43.6M
  • Description
  • Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in ...
More about ACHL
Track This Portfolio

Track Redmile Group, LLC Portfolio

Follow Redmile Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Redmile Group, LLC with notifications on news.